Search results
Results from the WOW.Com Content Network
Pramipexole, sold under the brand Mirapex among others, is a medication used to treat Parkinson's disease (PD) and restless legs syndrome (RLS). [8] In Parkinson's disease it may be used alone or together with levodopa . [ 8 ]
Dexpramipexole is the (D)-enantiomer of pramipexole. Enantiopure dexpramipexole has essentially no dopamine agonist activity and shares no other pharmacologic similarity to pramipexole. [ 10 ] In contrast, pramipexole the (S)-enantiomer is a dopamine agonist and is an approved drug (Mirapex) used in Parkinson's disease.
Its ability to activate both D 1-like and D 2-like receptors is similar to the case of apomorphine (which notably has greater efficacy in the treatment of Parkinson's disease than D 2-like-selective agonists but has suboptimal pharmacokinetic properties) and pergolide but unlike pramipexole and ropinirole. [15]
Ropinirole can cause nausea, dizziness, hallucinations, orthostatic hypotension, and sudden sleep attacks during the daytime.Unusual side effects specific to D 3 agonists such as ropinirole and pramipexole can include hypersexuality, punding and compulsive gambling, even in patients without a history of these behaviours.
Mevidalen (LY-3154207) is a dopaminergic drug which is under development for the treatment of Lewy body disease, including those with Parkinson's disease. [1] [2] [3 ...
The most frequent side effects include headache, insomnia, sleepiness, parkinsonism (effects similar to Parkinson's disease such as shaking, muscle stiffness and slow movement), dystonia (involuntary muscle contractions), tremor (shaking), dizziness, akathisia (restlessness), agitation, anxiety, depression, increased weight, nausea, vomiting, constipation, dyspepsia (heartburn), diarrhea, dry ...
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.
Opipramol, sold under the brand name Insidon among others, is an anxiolytic and tricyclic antidepressant that is used throughout Europe. [1] [4] [5] [6] [7] Despite ...